Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center
Archivos de la Sociedad Española de Oftalmología (English Edition) · 2025
DOI: 10.1016/j.oftale.2025.03.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archivos de la Sociedad Española de Oftalmología (English Edition), 2025. Verfasst von P D Lara-Barrera und 4 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Oftalmología Fundación de Asistencia Privada Conde de Valenciana IAP, Mexico City, Mexico. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Hemifacial Spasm, Blepharospasm, Neuromuscular Agents. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Blepharospasm is characterized by involuntary, sustained spasms of the orbicularis oculi, corrugator, and procerus muscles. Hemifacial spasm (HFS) is characterized by the involuntary tonic-clonic contraction of the muscles of a hemiface. The main role of botulinum toxin type A (BoNT-A) in the treatment of blepharospasm and HFS is recognized by guidelines around the world. In this study, we evaluated the applicability of botulinum toxin type A in patients with periocular hyperkinetic disorders at the Instituto de Oftalmología Fundación Conde de Valenciana, so that we can share the Mexican experience with the international evidence. MATERIALS AND METHODS: The clinical records of patients diagnosed with facial hyperkinetic disorders treated with botulinum toxin type A (BoNT-A) that were treated from January 2015 to September 2021 were analyzed. RESULTS: A total of 140 records of patients diagnosed with facial hyperkinetic disorder and treated with BoNT-A were analyzed. Facial hyperkinetic disorders that occurred included 5 (3.6%) patients with orbicularis oculi myokymia, 72 (51.4%) with blepharospasm, 62 (44.3%) with hemifacial spasm, and 1 (0.7%) with Meige syndrome. One hundred and twenty patients (85.7%) reported remission of initial symptoms after BoNT-A therapy during the period covered by this study. CONCLUSIONS: Botulinum toxin type A is effective and safe as a treatment for facial hyperkinetic disorders in the Mexican population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Oftalmología Fundación de Asistencia Privada Conde de Valenciana IAP, Mexico City, Mexico.
- Instituto de Oftalmología Fundación de Asistencia Privada Conde de Valenciana IAP, Mexico City, Mexico. Electronic address: angel.nava@condecentro.org.
Zitieren
APA
Lara-Barrera, P. D., Tovilla-Canales, J. L., Olvera-Morales, O., Castillo-Pérez, E. G., & Nava-Castañeda, Á. (2025). Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center. Archivos de la Sociedad Española de Oftalmología (English Edition). https://doi.org/10.1016/j.oftale.2025.03.009
Vancouver
Lara-Barrera PD, Tovilla-Canales JL, Olvera-Morales O, Castillo-Pérez EG, Nava-Castañeda Á. Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center. Archivos de la Sociedad Española de Oftalmología (English Edition). 2025. doi:10.1016/j.oftale.2025.03.009
BibTeX
@article{LaraBarrera2025,
author = {Lara-Barrera, P D and Tovilla-Canales, J L and Olvera-Morales, O and Castillo-Pérez, E G and Nava-Castañeda, Á},
title = {Experience of the application of botulinum toxin type A as a treatment of facial hyperkinetic disorders in a Mexican ophthalmological center},
journal = {Archivos de la Sociedad Española de Oftalmología (English Edition)},
year = {2025},
doi = {10.1016/j.oftale.2025.03.009}
}
EUVIMED